Innovative Engineered CAR-NK Cells Show Promise in Evasion of Immune Rejection and Enhanced Cancer Targeting
Researchers have developed engineered CAR-NK cells that can evade immune rejection and target cancer cells more effectively, promising safer and more accessible immunotherapy options.
Scientists from MIT and Harvard Medical School have developed a groundbreaking method to engineer CAR-NK (Chimeric Antigen Receptor-Natural Killer) cells that can better evade the immune system's defenses and more effectively target cancer cells. These immune cells, similar to the widely studied CAR-T cells, are reprogrammed to recognize and attack tumor cells, but a significant hurdle has been their rejection by the host immune response.
The new approach involves customizing CAR-NK cells to minimize their visibility to the patient’s immune system, specifically by reducing surface proteins called HLA class I proteins that normally trigger immune rejection. The researchers achieved this by engineering the cells to express short interfering RNA (siRNA) sequences to silence these proteins, while also introducing genes for proteins like PD-L1 or single-chain HLA-E (SCE) that bolster the NK cells’ ability to kill cancer cells.
In preclinical studies with mice possessing human-like immune systems, these modified CAR-NK cells demonstrated a remarkable ability to survive longer and nearly eradicate lymphoma tumors, outperforming unmodified or only CAR-expressing NK cells. Moreover, they showed a lower propensity to cause cytokine release syndrome, a dangerous side effect associated with immunotherapies.
This advancement paves the way for the development of off-the-shelf, ready-to-use CAR-NK therapies that can be administered immediately upon diagnosis, reducing the time and complexity associated with current personalized treatments. The team's work suggests that these CAR-NK cells could serve as a safer, more versatile alternative to CAR-T cells and may be adapted for treating various cancers, autoimmune diseases, and other conditions.
By enabling immune-evasive properties in NK cells, this research opens new horizons in cancer immunotherapy, promising more effective and accessible treatments in the near future.
Source: https://medicalxpress.com/news/2025-10-car-nk-cells-evade-immune.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
How Mosquito-Borne Viruses Invade the Brain's Defense Mechanisms
New UCLA research uncovers how mosquito-borne viruses breach the blood-brain barrier, revealing potential targets for future vaccines and therapies to prevent serious neurological infections.
High-Volume Exercise Linked to Increased Coronary Artery Calcification Scores
High-volume endurance exercise may increase the risk of coronary artery calcification in male athletes, highlighting the importance of tailored fitness strategies. Learn more about recent findings on exercise volume and heart health.
New Insights into Glioblastoma: Cell Clustering May Influence Tumor Aggressiveness
New research uncovers how glioblastoma cell clustering influences tumor severity. Dispersed cells show higher plasticity and treatment resistance, offering potential new therapeutic targets.
Experts Warn Menopause Misinformation Is Compromising Women's Care
Experts warn that misinformation and unnecessary hormone testing are harming menopause care, emphasizing the need for evidence-based practices and clinical diagnosis.